SciDev.Net
Science and Development Network
News, views and information about science, technology and the developing world
Tuberculosis kills over one and a half million people each year, while governments struggle with inadequate infrastructure and the increasing threat of drug-resistant strains and co-infection with HIV/AIDS.
(Photo credit: Gary Hampton/The Global Fund)
Opinions and Analysis
We can learn from XDR-TB treatment in Lima
A Peruvian clinic's treatment of extensively drug-resistant tuberculosis is an example to the developing world, says Mario C. Raviglione.
11 August 2008
|
EN
|
ES
Source: New England Journal of Medicine
Drug-resistant TB needs massive research increase
Multidrug-resistant TB needs more research to equip healthcare workers with the right tools, write Frank G. J. Cobelens and colleagues.
Doubts about WHO tuberculosis programme
11 February 2008
|
EN
Source: British Medical Journal
Policy Briefs
Controlling TB requires public awareness
An assessment of national tuberculosis policies in select countries emphasises the need for more public engagement.
27 June 2007
|
EN
Source: Open Society Institute
Addressing health policy in Myanmar
The challenge of setting policy priorities for infectious diseases in Myanmar's current political climate.
27 June 2007
|
EN
Source: PLoS Medicine
News and Features
Scientists use nanotech to 'upgrade' TB drugs
A TB medication that harnesses nanotechnology to cut treatment time and eliminate side effects has won a prestigious award.
29 September 2009
|
EN
First promising TB drug in decades, say researchers
A new tuberculosis drug found using an old method of drug discovery is the first in 40 years to have proved successful in trials.
Practical Guides
Effective TB reporting
Guidance on how journalists can help tackle TB through effective, frequent reporting on research, policy and the disease's human toll.
Information Services
Missed the Global Health Forum 2009?
Our blog, by SciDev.Net columnist Priya Shetty, will fill you in, as will our interview with the Global Forum's Gill Samuels